Egalet Corporation

Egalet Corporation, a fully integrated specialty pharmaceutical company, is dedicated to developing, manufacturing, and commercializing innovative treatments for pain and other conditions. Egalet boasts three approved products ARYMO™ ER (morphine sulfate) extended-release tablets, OXAYDO® (oxycodone HCI, USP) tablets, and SPRIX® (ketorolac tromethamine) Nasal Spray. Utilizing its proprietary Guardian™ Technology, Egalet is expanding its pipeline with clinical-stage product candidates including Egalet-002, a long-term opioid treatment for severe pain. This technology can be broadly applied across different pharmaceutical products and can be used to develop combination products with similar or different release profiles. The company was founded in 1995 and is headquartered in the United States. In September 2016, Egalet secured a significant $40.00M post-IPO debt investment. This injection of funds is an indication of investor confidence in Egalet's potential for growth and innovation in the competitive biopharma, biotechnology, and healthcare industries. Egalet's innovative approach to pain management and its strong product portfolio position it as an attractive investment opportunity for venture capitalists seeking to support cutting-edge pharmaceutical solutions. For more information on Egalet and its products, visit egalet.com.